🇺🇸 FDA
Pipeline program

Homoharringtonine

CGX-635-CML-201

Phase 2 small_molecule terminated

Quick answer

Homoharringtonine for Myeloid Leukemia, Chronic is a Phase 2 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Teva Pharma GmbH
Indication
Myeloid Leukemia, Chronic
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials